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Abstract: Barriers to recovering the excess treatment costs associated with health research from local organisations in
the United Kingdom can increase research costs, delay completion of high- quality studies and risk disenfranchising
health trusts and patients from participation. The authors demonstrate how the process for recovering excess treatment
costs at a local National Health Service (NHS) trust level in a multicentre study was inconsistent and resulted in excess
effort and cost to the research budget. An innovative example of how an organisation acting as a broker between
commissioners and researchers facilitated a more timely excess treatment cost agreement is highlighted.
Trial registration: Current Controlled Trials ISRCTN68798818, registered on 18 February 2014.
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Findings
Attributing the costs of health and social care research
and development (AcoRD)
The AcoRD guidance, introduced in May 2012, attri-
butes the cost of research in the National Health Service
(NHS) to research costs, NHS treatment costs or NHS
support costs based on the primary purpose of the activ-
ity [1]. This guidance is specific to research being under-
taken in the UK. As the NHS bears the cost of the
patient care, the costs of the interventions within a re-
search study are the NHS treatment costs. Where the
cost of an experimental treatment is greater than the
cost of usual care, it represents an ‘excess treatment cost’
(ETC), which is still viewed as part of the NHS treat-
ment costs to be recovered through normal commission-
ing processes [2].
Negotiating ETCs in the Big CACTUS study
The Big CACTUS study is a randomised controlled
trial investigating the cost effectiveness of self-managed
computer aphasia therapy compared with attention
control or usual care for community-dwelling patients
4 months or more after the onset of a stroke. The inter-
vention comprises computer exercises tailored to
individual needs by a speech and language therapist
(SLT) and support from an SLT/rehabilitation assistant
or volunteer [3].
A previous pilot study indicated that 285 participants
were required, necessitating 20 SLT departments to take
part, 13 of which are in England [4]. Based on the
AcoRD guidelines [1], as the trial intervention was being
delivered in addition to usual care, the SLT time, assist-
ant time, software and computers are all ETCs.
The impact of local bureaucracy
Local NHS organisations are responsible for recovering
the NHS treatment costs associated with research. As
independent legal entities, they can decide if and how to
address this, which resulted in a myriad of different
approaches to securing ETCs in the set-up of the
Big CACTUS project (Fig. 1).
In eight NHS trusts, the excess treatment sum of
£3,000 to 4,000 was considered too small to make an ap-
plication to a Care Commissioning Group (CCG) (Fig. 1),
and costs were met through trust reserves or director-
ates housing SLT departments (F and G) or through the
SLT departments themselves (H and I). The ETCs were
covered by research funds within local organisations
delivering the intervention at sites J, K, L and M. This is
notable, as AcORD suggests ETCs should be recovered
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through normal commissioning processes, which would
not use research funds to support clinical activity.
The ETCs were met by CCGs in five sites (A, B, C, D,
and E). In sites B and C, applications needed to be made
to more than one CCG for them to cover the costs
jointly. In site C, four CCGs were asked to share the cost
(£750 each). This request was refused by one of the four
CCGs, as they only wished to fund research into medi-
cinal products. Commissioners rejected an application
for ETCs at site H on the grounds that they ‘already pay
enough for stroke care’. Where ETCs are above £20,000,
per trust, application can be made for national subven-
tion funding. However, because Big CACTUS required
smaller sums, if the SLT departments were unable to
absorb the ETCs, the trust and its patients would have
been disenfranchised from participating in the study.
Figure 1 shows that the time taken for an organisation
to make a decision to fund ETCs ranged from 13 days
(2 weeks) to 124 days (18 weeks), with a mean of 59 days
(8.5 weeks). This caused delay in getting research gov-
ernance approvals and risked delaying the start of
recruitment, with potential implications for recruiting to
time and target.
The time taken to secure the ETCs for the study
(approximately £70,000) required approximately 127 days
of an experienced Clinical Trials Unit trial manager and
research assistant time, representing a cost of £45,950 to
the research budget. This time included identifying an
individual who knew about ETCs at each Trust, under-
standing the local processes at each Trust, completing
individual Trust application forms, making follow-up
telephone calls, sending additional information and fa-
cilitating negotiations between R&D departments, Trust
finance, directorates and SLT departments. Whilst we
were unable to establish the exact time and cost of local
SLT and R&D staff in the process, we estimate that these
would be similar to those borne by the clinical trials
unit. The total cost of the research time taken to negoti-
ate excess treatment costs was therefore greater than the
ETCs themselves for this study.
Excess treatment cost brokers
The Hampshire & Isle of Wight Comprehensive Local
Research Network (CLRN) and Thames Valley CLRN have
adopted an approach whereby they manage an annual
budget from the local commissioners for ETCs, thus being
brokers between researchers and commissioners [5]. They
proposed this model to provide standardised and timely
funding agreements, thereby enabling studies with ETCs
to be opened to recruitment without delay. The Big CAC-
TUS site E was covered by these networks. One applica-
tion was made by the research team to the CRN, and the
ETCs were approved in 2 weeks, the shortest time of all
the sites (Fig. 1).
Conclusion
At a time where cost efficiency and improving patient
care through high-quality research are key priorities, a
lack of streamlined processes to recover ETCs can
increase the cost of research, restrict Trust and patient
Fig. 1 Who pays the excess treatment costs (ETCs)? How long does it take to secure a decision?
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participation and risk the delivery of high-quality
studies. Identifying organisations who can be brokers
between commissioners and researchers could reduce
these barriers.
In November 2015, NHS England published further
guidance on excess treatment costs to clarify the




AcORD: Attributing the costs of health and social care research and
development; CCG: Care Commissioning Group; CLRN: Comprehensive Local
Research Network; ETC: Excess Treatment Costs; NHS: National Health Service;
SLT: Speech and Language Therapist.
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